GILEAD SCIENCES, INC. business relationships

“(1) For additional information regarding our collaborations with Merck, Arcellx and Arcus, see Note 7.” SEC filing

“(1) As of December 31, 2025, the majority of our Accounts receivable balance arises from product sales in the U.S. and Europe and approximately 60 % relates to three wholesalers-Cardinal Health, Cencora and McKesson-and their specialty distributor affiliates.” SEC filing

“(1) As of December 31, 2025, the majority of our Accounts receivable balance arises from product sales in the U.S. and Europe and approximately 60 % relates to three wholesalers-Cardinal Health, Cencora and McKesson-and their specialty distributor affiliates.” SEC filing

“• Entered into an exclusive option and license agreement with Kymera Therapeutics, Inc. to develop novel oral molecular glue CDK2 degraders with broad oncology treatment potential.” SEC filing

“Historically, approximately 90% of our gross product sales in the U.S. have been to three wholesalers-Cardinal Health, Inc., Cencora, Inc. and McKesson Corporation-and their specialty distributor affiliates.” SEC filing

“In collaboration with Arcus Biosciences, Inc. ("Arcus") (1) , the combination of domvanalimab, an Fc-silent anti-TIGIT antibody, and zimberelimab, an anti-PD-1 monoclonal antibody, with chemotherapy, is being evaluated as a first-line treatment for metastatic NSCLC.” SEC filing

“...t global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceut...” SEC filing

“...een the parties (each, an "Option and License Agreement" and together, the "Option and License Agreements"), we granted Gilead exclusive options to license exclusively ("License Option") our bispecific antibody, AGEN1223, and our monospecific antibody, AGEN2373 (together, the "Option Programs"), dur...” SEC filing

“...an a broad collaboration with Incyte to pursue the discovery and development of antibodies, in December 2018 we entered into a partnership with Gilead relating to five of our antibody programs and in May 2021 we entered into a license agreement with BMS relating to our anti-TIGIT bispecific antibody” SEC filing

“with Gilead (Gilead Collaboration Agreement) to research and develop trispecific T-cell engaging antibody product” SEC filing

“...ed milestones paid to Agenus on six-partnered oncology programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as "Agenus Partnered Programs"), and (ii) a synthetic 2.625 % royal...” SEC filing

“Collaboration and License Agreement by and between the Company and Gilead Sciences, Inc., dated October 14, 2022 (incorporated by reference to Exhibit 10.22 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)” SEC filing

“The Company is also collaborating with Gilead Sciences, Inc. ( Gilead) on the development of MGD024, a bispecific DART antibody targeting CD123 and CD3 that utilizes its next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical development programs.” SEC filing

“Additionally, there are two known small pharmaceutical companies developing programs with various mechanisms of action, including Huahui Health and Assembly Biosciences (in partnership with Gilead).” SEC filing

“In January 2020, the Company entered into a Technology License Agreement (the "Gilead Agreement") with Gilead, pursuant to which the Company granted Gilead an exclusive license to its Cytotoxic Fc and Xtend Fc technologies for an initial identified antibody and options for up to three additional ant...” SEC filing

“Autologous T cell therapies directed at CD19 have been commercialized by Novartis, Kite/Gilead and Bristol-Myers Squibb Company (BMS) and are witnessing increased adoption in the marketplace.” SEC filing

“At the commencement of the arrangement, the Company concluded Gilead was a customer and accordingly, the Gilead Collaboration Agreement was within the scope of the revenue from contracts with customers guidance.” SEC filing

“Under the Gilead Collaboration Agreement, Gilead exclusively licensed to the Company its HPI program and NNPI program, while retaining opt-in rights to these programs and has an option to take an exclusive license, on a program-by-program basis, to all of the Company's other current and future pipel...” SEC filing

“For additional information regarding the Gilead Collaboration, see "Collaboration and License Agreements-Gilead Sciences, Inc."” SEC filing

“We expect our collaboration with Gilead to be a critical part of the development, manufacture and commercialization of our product candidates.” SEC filing

“GS-0321 (previously COM503) is licensed to Gilead and is” SEC filing

“Pursuant to the license agreement, Gilead paid us a $60 million upfront license payment” SEC filing

“Strategy and Partnerships - Gilead License", and "Item 4.” SEC filing

“The Company also determined that the IND research and development activities and Phase 1 research and development activities could be provided by resources otherwise available to Gilead and thus are capable of being distinct.” SEC filing

“Gilead has been awarded the contract in Louisiana and other states and AbbVie has been awarded the contract in Washington and other states.” SEC filing

“The intellectual property rights co-owned by Pulmokine and Gilead Sciences are subject to a license agreement, or the Gilead Agreement, between Pulmokine and Gilead Sciences.” SEC filing

“On February 12, 2025, we entered into the Second Gilead CSCSA with Gilead pursuant to which we and Gilead will collaborate on a portion of our Phase 1 study for the clinical evaluation of IDE397 in combination with Trodelvy (the Combination Study), in certain patients with advanced solid tumors in l...” SEC filing

“Clinical Study Collaboration and Supply Agreement with Gilead for IDE397” SEC filing

“On December 19, 2018, we entered into a three-year collaboration with Gilead to discover and develop therapeutics that target TGFβ-driven signaling, a central regulator of fibrosis ("the Gilead Agreement").” SEC filing

“The Company evaluated the Gilead Agreement under ASC 606, Revenue from Contracts with Customers, and determined that the arrangement represents a contract with a customer.” SEC filing

“Option and license agreement with Gilead Sciences” SEC filing

“For example, we granted our collaboration partner Gilead an exclusive option for an exclusive license with respect to our CDK2 program, and future payments under our licensing arrangement with Gilead are contingent upon Gilead's exercise of this option.” SEC filing

“Collaboration, Option and License Agreement, dated June 10, 2019, by and between the Registrant and Gilead Sciences, Inc., as amended” SEC filing

“Our partnership efforts are focused on the advancement of a robust and sustainable pipeline in collaboration with our partners Gilead, Sanofi, and Pfizer.” SEC filing

“There was no financial penalty to the Company as a result, no licensed programs were returned to the Company, all ongoing work at Gilead on licensed programs will continue and agreements for all future milestones and royalties remain in effect.” SEC filing

“In August 2020, the Company and Gilead entered into an Amended Research Collaboration and License Agreement (the Gilead Agreement), which superseded and replaced the 2018 Gilead Agreement.” SEC filing

“costs to fulfill our obligations under the collaboration with Gilead through August 2025;” SEC filing

“In that circumstance, we would need to obtain a license from Gilead Sciences, which may not be available on reasonable terms, if at all.” SEC filing

“In January 2020, the Company entered into the Collaboration, Option and License Agreement (the "Gilead Agreement") with Gilead Sciences, Inc. ("Gilead").” SEC filing

“All commercial economics on filgotinib in Europe transferred to us as of January 1, 2022, subject to payment of tiered royalties of 8 to 15% of net sales in Europe to Gilead, starting in 2024 .” SEC filing

“For the year ended December 31, 2025 we recognized in revenue € 12.2 million of royalties from Gilead on filgotinib.” SEC filing

“Under the agreement as revised in 2019, we and Gilead would co-commercialize filgotinib in France, Germany, Italy, Spain and the United Kingdom and retain the 50/50 profit share in these countries that was part of the original filgotinib license agreement.” SEC filing

“The revenues from our collaboration partner Gilead represented 97 % of our total net revenues from continuing operations in 2025 ( 87 % in 2024, nearly 100 % in 2023).” SEC filing

“In addition, we are heavily dependent on Gilead for the commercialization of filgotinib.” SEC filing

“Other companies with selective KRAS inhibitors include AstraZeneca (in collaboration with Usynova), BioNTech, Roche, Merck/Moderna, Boehringer and Gilead.” SEC filing

“Exclusive License Agreement with Gilead” SEC filing

“...ing multiple programs in preclinical and clinical development, including masked multi-specifics, and our clinically-validated masking technology has enabled us to establish top-tier strategic partnerships, including with AbbVie Group Holdings Limited, or AbbVie, and Gilead Sciences, Inc., or Gilead.” SEC filing

“Revenues from Gilead accounted for 97 %, 94 % and 96 % of Total revenues for the years ended December 31, 2025, 2024 and 2023, respectively.” SEC filing

“With respect to quemliclustat, domvanalimab and zimberelimab and subject to timely exercise of Gilead's and Taiho's respective option rights to other molecules in our pipeline, as discussed below, Gilead has certain commercialization rights under the Gilead Collaboration Agreement, and Taiho has com...” SEC filing

“Given the breadth of the collaboration with Gilead, our ability to form new collaborations in the future will be limited.” SEC filing

“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing